TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
NKTR

Nektar Therapeutics

Healthcare · Biotechnology

57.10$ -3.9% vs. previous close Closing price · As of: Sep 25, 2026

Ownership

Ownership Structure

Who owns Nektar Therapeutics (NKTR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 83.6% of the shares are freely tradable; institutional investors hold 92.1%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 92.1%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 83.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 19.6%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 34Mio.

Largest Shareholders

Institutions

Institutions NKTR
Name Stake (%) Shares Change (%) Date
FMR Inc 12.60 4,303,188 +4,155.1 03/31/2026
Bvf Inc 7.50 2,559,595 +64.1 03/31/2026
Two Seas Capital LP 5.74 1,959,178 +162.9 03/31/2026
Two Sigma Investments LLC 3.52 1,202,004 +29.1 06/30/2026
Vanguard Capital Management, LLC 3.51 1,197,055 +0.0 03/31/2026
Prosight Management, LP 2.37 810,000 +10.2 06/30/2026
BlackRock Inc 2.03 692,650 +7.3 03/31/2026

Funds

Funds NKTR
Name Stake (%) Shares Change (%) Date
Fidelity Growth Company Fund 5.36 1,831,737 +0.0 07/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 3.16 1,077,897 -0.1 08/31/2026
iShares Russell 2000 ETF 2.59 882,671 -0.6 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings NKTR
Person Role Shares Value As of Type
Robin Howard W President & CEO 54,627 3,119,202 $ Aug 18, 2026 direct
Greer R Scott Director 22,239 1,269,847 $ Sep 23, 2026 direct
Chess Robert Director 19,019 1,085,985 $ Sep 23, 2026 direct
Whitfield Roy A Director 16,417 937,411 $ Sep 23, 2026 direct
Zalevsky Jonathan Chief R&D Officer 9,570 546,447 $ Aug 18, 2026 direct
Ajer Jeffrey Robert Director 4,277 244,217 $ Sep 23, 2026 direct
Brainard Diana Director 3,904 222,918 $ Sep 23, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Sep 23, 2026 Whitfield Roy A Director Other 2,000 0.00 –
Sep 23, 2026 Greer R Scott Director Other 2,000 0.00 –
Sep 23, 2026 Chess Robert Director Other 2,000 0.00 –
Sep 23, 2026 Brainard Diana Director Other 2,000 0.00 –
Sep 23, 2026 Ajer Jeffrey Robert Director Other 2,000 0.00 –
Aug 18, 2026 Zalevsky Jonathan Chief R&D Officer Sell 186 71.98 13,388
Aug 18, 2026 Robin Howard W President & CEO Sell 418 71.98 30,088

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?